1. Introduction {#sec1}
===============

In people with long-standing type 1 diabetes (T1D), sodium-glucose cotransporter (SGLT) inhibitors improve glucose control, decrease insulin requirement and promote weight loss \[[@bib1]\], but also predispose to genital infection and ketoacidosis \[[@bib2]\]. SGLT inhibitors have not been widely used in recent-onset T1D, primarily due to concern about the risk of ketoacidosis \[[@bib3]\]. This would be an unreasonable burden for patients to manage while they are adjusting to their diagnosis and learning how to manage their diabetes. However, the presence of residual beta cell function at diagnosis of T1D \[[@bib4]\] is likely to decrease the risk of ketosis with SGLT inhibitor treatment \[[@bib3]\]. Furthermore, improved postprandial glucose control, observed in people with long-standing T1D who received sotagliflozin \[[@bib5]\], may be particularly helpful in recent-onset T1D by decreasing bolus insulin requirements and simplifying insulin regimens. An argument can be made to evaluate SGLT inhibition as a treatment adjunct in recent-onset T1D provided side-effects are tolerable. Therefore, as a prelude to a randomised control trial, we first sought to determine the feasibility and safety of the SGLT2 inhibitor, empagliflozin, in patients with recent-onset T1D.

2. Materials and methods {#sec2}
========================

2.1. Patients and setting {#sec2.1}
-------------------------

The study was conducted at Royal Melbourne Hospital between January 2017 and May 2019 and registered as ACTRN12617000016336. Inclusion criteria were age 18-40 years, T1D diagnosed within 100 days of starting empagliflozin, presence of at least one islet autoantibody and meal-stimulated plasma C-peptide \>0.07 nmol/L. Exclusion criteria were a co-morbidity deemed to pose unacceptable risk, pregnancy or planned pregnancy, breast feeding or, if female, refusal to use effective contraception.

2.2. Interventions and data collection {#sec2.2}
--------------------------------------

At weeks 0, 12, 24 and 36, participants undertook routine biochemistry, completed a diabetes distress survey \[[@bib6]\] and wore a Minimed™ iPro™2 continuous glucose monitor (CGM; Medtronic Minimed™, Northridge, CA) for one week. Mixed meal tolerance tests were performed at the same intervals to determine beta-cell function, calculated by dividing the trapezoidal area under the C-peptide curve by 120 min \[[@bib7]\]. Empagliflozin was withheld three days prior to meal tests at weeks 12 and 24 to avoid potential effects on C-peptide release.

At weeks 4, 8, 18 and 30, additional visits were scheduled to review glucose control. Participants accessed dietician and diabetes educator support at all study visits to target fasting and postprandial glucose to 5 mmol/L and 10 mmol/L respectively. They monitored capillary ketone concentrations weekly using an Optium Neo device (Abbott, Doncaster, Australia).

Adherence with empagliflozin (25 mg daily from weeks 0--24) was assessed by urine dipstick testing for glucose and by counting tablets.

2.3. Outcomes {#sec2.3}
-------------

The primary outcome of feasibility was assessed as adherence with the study protocol and safety. Secondary outcomes were numbers and severity of adverse events, body weight, stimulated C-peptide, HbA1c, insulin dose, CGM measures and diabetes distress score \[[@bib6]\].

2.4. Statistical analyses {#sec2.4}
-------------------------

Data were complete with the exception of CGM results at week 12 for one participant, which were imputed by averaging the measures at 0 and 24 weeks. Statistical analyses were performed with Prism software (V8, GraphPad, San Diego, CA). The Friedman test was used to assess differences across time, with correction for multiple comparisons by the two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli \[[@bib8]\].

3. Results {#sec3}
==========

3.1. Participant recruitment and baseline characteristics {#sec3.1}
---------------------------------------------------------

Sixty-one individuals were referred to the study. Fifteen did not meet eligibility and 32 declined to participate due to perceived treatment risks and the study demands. All 14 participants who enrolled were on multiple daily insulin injections. Their baseline characteristics are presented in [Table 1](#tbl1){ref-type="table"}. Median \[Q1, Q3\] age was 26 \[22, 32\] years, body mass index 24 \[23, 26\] kg/m^2^, disease duration 72 \[54, 92\] days and HbA1c 7.1 \[6.1, 8.5\] percentage units (54 \[42, 69\] mmol/mol).Table 1Baseline characteristics.Table 1IDSexAge (years)Diabetes duration[a](#tbl1fna){ref-type="table-fn"} (days)Weight (kg)BMI (kg/m^2^)DKA at diagnosisPolyuria/polydipsia at diagnosisAntibody specificityHLA-DR genotypeHbA1c (%)HbA1c (mmol/mol)Insulin dose (U/kg/day)Stimulated C-peptide (nmol/l)1M315895.326.4YesYesGAD, ZnT84/X8.3670.240.5242F189284.133.7NoNoGAD, ZnT84/X6.0420.271.1693M229263.721.5YesYesGAD3/36.0420.360.4894F349477.725.1YesYesGADNP6.5470.120.6405M227281.225.9NoYesGAD, IA24/X5.9410.150.9206M278084.024.0NoYesGAD, IA24/48.1650.180.3997M189682.926.2NoYesGAD, IA2, ZnT83/35.9410.440.4938M225582.924.2NoYesGAD, IA2, ZnT83/47.6600.111.0429M277280.025.0NoYesGAD3/46.5480.401.08410F372864.522.5NoYesZnT84/X10.4900.220.39211M317276.124.0NoYesGAD, IA2, ZnT83/46.5480.120.43512M226865.822.8NoYesGAD3/X9.5801.520.28313F255056.319.7NoYesGAD, ZnT83/38.9740.520.86514M362871.823.3NoYesGAD, ZnT84/X7.9630.350.552[^1][^2]

3.2. Medication adherence and safety {#sec3.2}
------------------------------------

The median rate of empagliflozin adherence was 0.89 \[0.74, 1.0\]. Four serious adverse events (SAEs) affecting four participants were observed. One (alcohol intoxication without ketosis) occurred during week 24 and the other three (concussion, finger dislocation and supraventricular tachycardia) occurred during weeks 24--36, after empagliflozin was ceased.

3.3. Other adverse events {#sec3.3}
-------------------------

During weeks 0--24, 14 episodes of generalised fatigue affected 9 participants. These episodes were associated with capillary blood glucose readings in the lower range (between 3.5 and 6 mmol/l) and resolved after 1-5 days in 7 of the affected participants. However, fatigue was sufficiently severe to prompt 2 participants to stop taking empagliflozin: one noted fatigue in week 1 and withdrew from the trial; the other took the tablet intermittently over the first 10 weeks due to fatigue before stopping it. On re-exposure during week 16, fatigue recurred and no further doses were taken. In addition, 5 episodes of mild to moderate genital infection affected four participants, all of whom received topical or oral anti-fungal treatment for up to a week and continued taking empagliflozin.

3.4. Capillary ketone measures {#sec3.4}
------------------------------

During the 24-week empagliflozin treatment phase, the 13 participants who completed the study performed a median \[Q1, Q3\] of 35 \[20, 66\] home capillary ketone measurements, only one of which exceeded 1 mmol/l. This occurred in week 15 associated with headache, that resolved after 4 h, when ketones were 0.6 mmol/l.

3.5. Diabetes outcomes {#sec3.5}
----------------------

After 24 weeks, median body weight decreased by 4.4 kg and median HbA1c by 1.5% units (17 mmol/mol; [Fig. 1](#fig1){ref-type="fig"}a and b). Insulin doses decreased to week 24 and then increased ([Fig. 1](#fig1){ref-type="fig"}c), with 4 participants stopping bolus insulin for at least a month. Meal-stimulated C-peptide did not change significantly during the first 24 weeks and then decreased ([Fig. 1](#fig1){ref-type="fig"}d and e). CGM mean glucose decreased initially and then increased between weeks 12 and 36 ([Fig. 1](#fig1){ref-type="fig"}f), while glucose time within and below range, and %CV did not change significantly ([Fig. 1](#fig1){ref-type="fig"}g, h, i). Diabetes distress did not change significantly ([Fig. 1](#fig1){ref-type="fig"}j).Fig. 1***Clinical outcomes for the 13 participants who completed the study***. Weight (a), HbA1c (b), insulin dose (c), meal-stimulated C-peptide (d, e), CGM measures of mean daily glucose (f), time between 3.9 and 10 mmol/L (g), time \<3.9 mmol/L (h) and glucose variability %CV (i), and diabetes distress score (j) are shown as median with interquartile range. The grey shaded area corresponds to the empagliflozin treatment phase from weeks 0--24. \*, \*\* and \*\*\* depict p \< 0.05, \<0.01 and \< 0.001 respectively.Fig. 1

4. Discussion {#sec4}
=============

We demonstrate a high level of treatment adherence and no concerning ketosis or other adverse events when empagliflozin 25 mg daily was combined with basal/bolus insulin therapy within 100 days of T1D diagnosis. Empagliflozin treatment was associated with decreased body weight and improved glucose control despite decreased frequency and doses of insulin injections. Together, these findings demonstrate the feasibility of this approach to T1D therapy, and suggest it may deliver clinical benefit.

Strengths of this study include the prospective collection of measures of capillary ketones, CGM data and beta-cell function (meal-stimulated C-peptide). Ketoacidosis is reported to occur at a rate of 5 events per 100 patient years in established T1D \[[@bib3]\]. Our sample size was too small to determine the risk of ketoacidosis but the finding of only one home ketone measurement over 1 mmol/l suggests it was not increased by treatment with empagliflozin. Glucose time in the 3.9--10 mmol/l range did not improve during empagliflozin treatment, in contrast to prior studies of SGLT inhibitors in long-standing T1D \[[@bib5],[@bib9],[@bib10]\]. However, at baseline, the percentage of time in range was much lower in these studies (40-52% compared to 83% in this study), so any change with SGLT inhibitor treatment would have been smaller in magnitude and therefore more difficult to detect. Meal-stimulated C-peptide did not change significantly during the 24-week treatment phase, indicating no substantial effect of empagliflozin on beta-cell function. The significant decrease in C-peptide between weeks 24 and 36 during the washout phase does however raise the possibility that empagliflozin might preserve beta-cell function in recent-onset T1D. Because the visit schedule of this study mirrored that used by trials of disease-modifying therapy in T1D (e.g. Ref. \[[@bib11]\]), our outcome data should aid the design of a placebo-controlled trial involving a similar population to determine the effects of SGLT inhibition on beta-cell function.

This study identified two common adverse events that may limit tolerability of SGLT inhibitors in recent-onset T1D. Genital infection was not unexpected \[[@bib9],[@bib10],[@bib12]\] and was mild to moderate in severity. However, the observation of generalised fatigue affecting 9 participants and causing 2 to stop empagliflozin treatment early was unexpected. Its association with low-normal capillary glucose measures suggests this side-effect might be alleviated by gradual dose escalation of empagliflozin.

5. Conclusion {#sec5}
=============

Our findings provide support for a definitive trial to determine the effects of SGLT inhibitors on clinical outcomes and on beta-cell function, either alone or in combination with newer non-insulin therapies \[[@bib11],[@bib13]\].
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[^1]: NP: not performed.

[^2]: at time of taking first dose of empagliflozin.
